Results 41 to 50 of about 734,056 (162)

Intravenous -acetylcysteine in severe cutaneous drug reaction treatment: A case series

SAGE Open Medical Case Reports, 2020
Drug-induced serious adverse reaction is an unpleasant event with high rate of mortality. Stevens–Johnson Syndrome and toxic epidermal necrolysis are most common among the serious adverse drug reactions.
Md Jahidul Hasan, Raihan Rabbani
doaj   +1 more source

Increased predisposition of sjs ten in COVID-19 patients, presenting as post COVID complication: Report of two cases

Indian Dermatology Online Journal, 2022
We report two consecutive cases of toxic epidermal necrolysis presented to our emergency department in the past 5 months. Both patients had history of fever prior to the onset of skin manifestations and showed radiological findings suggestive of COVID-19
Shayna Aulakh, Raina Arora, Rishu Sarangal, Dimple Chopra   +3 more
doaj   +1 more source

Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report

Journal of Medical Case Reports, 2012
Introduction Toxic epidermal necrolysis lies within the spectrum of severe cutaneous adverse reactions induced by drugs, affecting skin and mucous membranes.
Kamal Tamer, Elnikety Sherif, Mashaly Heba, Casha James   +3 more
doaj   +1 more source

Toxic Epidermal Necrolysis

Journal of Rawalpindi Medical College, 2020
Toxic epidermal necrolysis (TEN) is the most severe form of drug-induced skin reaction and includes denudation of >30% of total body surface area. The mechanism of disease is not completely understood, but immunologic mechanisms, cytotoxic reactions, and
Syed Naveed Ali Shah, Ifaza Tariq, Muhammad Nauman Zafar   +2 more
doaj  

Carbamazepine-Induced Toxic Epidermal Necrolysis

Journal of Integrated Health Sciences, 2018
Toxic epidermal necrolysis (TEN) is an uncommon; however, life-threatening dermatological condition which occurs most frequently by the use of drugs. Some group of medications, such as antiepileptics, antibiotics as well as antivirals, can induce such ...
Kushal Gohel, Rashmi Mahajan, Megha Patel, Harsh Patel   +3 more
doaj   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source

The characteristic dermoscopic features of Stevens–Johnson syndrome and toxic epidermal necrolysis.

, 2021
The characteristic dermoscopic features of Stevens–Johnson syndrome and toxic epidermal ...
Shen, M (via Mendeley Data), Shen, Meng-Han   +1 more
core   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Toxic Epidermal Necrolysis

Eurasian Journal of Medicine, 2019
-
Gülten Gürel, Ökkeş Sipahi, Faik Gençer   +2 more
doaj   +2 more sources

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska, Izak A. R. Yasrebi‐de Kom, Nicolette F. de Keizer, Dave A. Dongelmans, on behalf of the RESCUE Study group, Merijn C. Reuland, Irma M. Rigter, Peter F. Schutte, Ilona T. Spaan, Dorieke van Balen, Stefaan Hendriks, Petronella E. Deetman, Cedric Lau, Wytze J. Vermeijden, Marieke G. J. Schouten, Joost B. Masselink, Peter E. Spronk, Marnix Kuindersma, Hendrikus J. M. van Kan, Anne Wellink, Abraham J. Valkenburg, Andre Wieringa, Walter M. van den Bergh, Maurits H. Renes, Wouter Bult, Frouke M. Engelaer, Nienke van Rein, Martijn Hoeksema, Janneke M. van den Broek, Elsbeth Wesselink, Ilse M. Purmer, Thomas Ottens, Bertha E. Bosma, Sjoerd H. W. van Bree, Barbara Festen, Hendrick J. W. Lammers, Rob J. Bosman, Rogier M. Determann, Eric J. F. Franssen, Attila Karakus, Lenneke. E. M. Haas, Freek van Gorp, Dylan W. de Lange, Maaike A. Sikma, Esther V. Uijtendaal   +44 more
wiley   +1 more source